AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$SKYH

Gonzalez Francisco purchased $15K of SKYH

Gonzalez Francisco (Chief Financial Officer) purchased 1,500 shares of Sky Harbour Group Corp (SKYH) at $9.69 on 2026-09-30.

Original reporting
SEC EDGAR · Gonzalez Francisco
Published Oct 1, 2026, 2:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 2:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYH
Neutral
high confidence
Mentioned
$SKYH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYHNeutralLow
01

Why it matters

The transaction adds a modest increase to insider ownership, offering a slight confidence cue but unlikely to affect trading decisions materially.

02

Market read

Primary insider purchase of modest size; low trading relevance.

03

What to watch

No disclosed 10b5-1 plan; could indicate discretionary buying, but size remains trivial.

Relevance 4/10Novelty 4/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions; CFO's purchase is the first public report of this activity.

Company-level read

Ticker impact

$SKYHNeutralHigh confidence
Context

CFO Gonzalez Francisco bought 1,500 shares for $14,535, increasing his stake to 713,088 shares.

Expected impact

slight upward pressure as market views insider buying positively

Evidence & confidence

Form 4 is primary source; transaction size is modest relative to market cap, so impact is limited.

Market effects

Sector

Minimal effect on aerospace/defense sector; insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase may be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Company
    Sky Harbour Group Corp

    Aerospace and defense contractor listed on Nasdaq under ticker SKYH.

  • Person
    Gonzalez Francisco

    Chief Financial Officer of Sky Harbour Group Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYH insider trading history →

Related articles

AUG 13
$SKYHMedAI 8/10

Sky Harbour announces $40 million equity financing deal

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

theglobeandmail.com3 min
AUG 12
$SKYHMed

Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

SEC EDGAR 8-K6 min
JUN 30
$SKYHMedAI 8/10

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.

finanznachrichten.de6 min